Last reviewed · How we verify
CHF 718 pMDI
CHF 718 pMDI is a corticosteroid used to reduce inflammation in the airways.
CHF 718 pMDI is a corticosteroid used to reduce inflammation in the airways. Used for Maintenance treatment of asthma, Treatment of chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | CHF 718 pMDI |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the release of pro-inflammatory mediators from mast cells and other cells in the airways, thereby reducing inflammation and improving symptoms in patients with asthma and other respiratory conditions.
Approved indications
- Maintenance treatment of asthma
- Treatment of chronic obstructive pulmonary disease (COPD)
Common side effects
- Oral thrush
- Hoarseness
- Cough
- Headache
- Nausea
Key clinical trials
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid (PHASE3)
- An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF 718 pMDI CI brief — competitive landscape report
- CHF 718 pMDI updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI